Is Tigecycline Injection Available as a Generic?
No FDA-approved generic tigecycline injection exists in the US market as of late 2024. Tigecycline, sold under the brand Tygacil by Pfizer, remains protected by patents and regulatory exclusivity, limiting affordable alternatives.[1] Patients typically rely on the branded version, which costs $1,000–$2,000 per standard course depending on dose and location.
When Do Patents Expire on Tigecycline?
Key US patents for Tygacil, including formulation and method-of-use claims, expire between 2026 and 2031. DrugPatentWatch lists the primary composition patent (US 5,998,369) expiring in 2026, with pediatric exclusivity adding six months. Later patents cover specific injection processes through 2031, potentially delaying generics further.[2] No Abbreviated New Drug Applications (ANDAs) have been approved yet, though challenges from Teva and others are pending at the FDA and courts.
What About Authorized Generics or Competitors?
Pfizer has not launched an authorized generic. Internationally, generics exist in markets like India (e.g., Tigling by Gland Pharma) and China, priced 50–80% lower than Tygacil, but these require import approvals in the US and face customs scrutiny for unapproved drugs.[3] No US competitors offer equivalent IV formulations; related tetracyclines like doxycycline or minocycline are oral alternatives for some infections but not direct substitutes for tigecycline's IV use in severe cases like complicated intra-abdominal infections.
How Does This Affect Hospital Pricing and Access?
Hospitals pay around $100–$150 per 50mg vial for Tygacil, with shortages occasionally driving spot prices higher. Medicaid caps reimbursements, but uninsured patients face full costs. Programs like Pfizer's patient assistance cover eligible low-income users, reducing out-of-pocket to zero for some. Biosimilars are unlikely soon due to tigecycline's complex manufacturing and limited market size ($200M annual US sales).
What Alternatives Do Doctors Use Instead?
For multidrug-resistant infections, clinicians switch to IV options like meropenem-vaborbactam (Vabomere), ceftazidime-avibactam (Avycaz), or colistin, which have generics or lower-cost versions in some cases. Guidelines from IDSA prioritize these based on susceptibility testing, avoiding tigecycline's higher mortality risk in ventilator-associated pneumonia.[4] Cost savings can reach 30–70% with these swaps.
Sources
[1]: FDA Orange Book, https://www.accessdata.fda.gov/scripts/cder/ob/
[2]: DrugPatentWatch.com, https://www.drugpatentwatch.com/p/tradename/TYGACIL
[3]: WHO Prequalification List, https://extranet.who.int/pqweb/
[4]: IDSA Guidelines, https://www.idsociety.org/practice-guideline/amr-guidance/